LARGE B-CELL LYMPHOMA

This early-phase study is testing whether a second infusion of the CAR T-cell therapy axicabtagene ciloleucel (Axi-Cel-2) is safe for adults with high-risk large B-cell lymphoma whose cancer came back or didn't respond to the first standard CAR T treatment. About 20 participants …

This early-phase study tests whether a drug called NT-I7 can safely boost the effects of CAR T-cell therapy in people with large B-cell lymphoma that has come back or not responded to treatment. About 24 participants will receive NT-I7 after standard CAR T therapy. The goal is to…

This study tests a combination of three drugs (glofitamab, a PD-1 inhibitor, and lenalidomide) in 24 people with a specific, hard-to-treat type of large B-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combination can shrink or eliminat…

This trial tests a new treatment called WZTL-002 for people with large B-cell lymphoma that has come back or not responded to standard chemotherapy. WZTL-002 uses a patient's own immune cells, which are modified in a lab to better attack cancer cells. The study will check how oft…

This study looks back at 250 adults with large B-cell lymphoma who received Glofitamab through a special access program in France. Researchers want to see how effective and safe the drug is in real-life settings, especially for patients whose cancer returned after CAR-T therapy. …

This phase 3 trial tests a new CAR T-cell therapy called rondecabtagene autoleucel (ronde-cel) that targets two proteins (CD19 and CD20) on lymphoma cells. It is compared to standard CD19-targeting CAR T-cell therapy in 400 patients with relapsed or refractory large B-cell lympho…

This early-stage study tests a new gene therapy called VNX-101 for people with blood cancers (like some leukemias and lymphomas) that have returned or not responded to standard treatments. The therapy uses a harmless virus to deliver a gene that helps the immune system target and…

This study tests whether giving an extra antibody drug after CAR-T cell therapy can improve outcomes for people with aggressive large B-cell lymphoma that has come back or not responded to prior treatments. About 23 participants will receive either mosunetuzumab or glofitamab (pl…

This study tests a new treatment called ronde-cel for people with aggressive B-cell lymphoma that has come back or not responded to at least two prior therapies. Ronde-cel is made from the patient's own immune cells, which are reprogrammed to target two markers on cancer cells (C…

This study tests a drug called loncastuximab tesirine (lonca) in people with large B-cell lymphoma that did not fully respond to CAR T-cell therapy. The goal is to see if lonca can turn a partial response into a complete response and help control the disease. About 30 adults will…

This study tests whether adding the drug epcoritamab to a standard, gentler chemotherapy mix (R-miniCVP) can help control newly diagnosed diffuse large B-cell lymphoma in older or frail adults who cannot tolerate stronger chemo. About 40 participants will receive the combination …

This study tests a new cell therapy called cemacabtagene ansegedleucel (cema-cel) in adults with large B-cell lymphoma who still have tiny amounts of cancer cells (minimal residual disease) after finishing their first standard treatment. About 250 participants will be randomly as…

This study tests whether giving focused radiation to large tumors before CAR-T cell therapy can help control aggressive large B-cell lymphoma that has come back or not responded to treatment. About 27 adults with tumors at least 5 cm will receive this combination. The goal is to …

This study is testing a new training program called Hematolo-GIST to help doctors communicate with patients who have large B-cell lymphoma. The goal is to see if the training is practical and helpful for both doctors and patients. About 48 people will take part.

This study aims to find out what factors help predict whether CAR-T therapy will work well for people with relapsed or refractory large B-cell lymphoma. Researchers will look at patient characteristics, tumor features, and immune system changes in 80 participants. The goal is to …